- Open Access
Pinocembrin ameliorates intermittent hypoxia-induced neuroinflammation through BNIP3-dependent mitophagy in a murine model of sleep apnea
Journal of Neuroinflammation volume 17, Article number: 337 (2020)
Intermittent hypoxia (IH) caused by obstructive sleep apnea (OSA) leads to neuroinflammation. Pinocembrin has been shown to have neuroprotective effects, while the therapeutic functions under IH condition are still unknown.
An OSA model was established by CIH exposure inside custom-made chambers. C57BL/6 mice were intraperitoneally injected with pinocembrin (40 mg/kg, i.p.) or vehicle (PBS containing 5% povidone; i.p.), and the changes of behavior on mice were detected by the Morris water maze test. Immunohistochemical staining, western blotting, immunofluorescence assays, and immunoprecipitation were used to investigate the association between NLRP3 inflammasome and BNIP3-dependent mitophagy. The mitochondrial morphology and mitophagosomes were detected under a transmission electron microscope. The detrimental effects of IH were tested by annexin V-FITC/PI staining, Mito SOX Red staining, and JC-1 mitochondrial membrane potential assay.
In this study, our observations in vivo indicated that the administration of pinocembrin can restore spatial learning and memory ability and reduce neuronal apoptosis and hippocampal inflammation. Pinocembrin treatment significantly inhibited the formation of NLRP3 inflammasome and infiltration of microglia and enhanced BNIP3-mediated mitophagy in the hippocampus of IH mice. Additionally, our in vitro results show that pinocembrin protects microglial cells against IH-induced cytotoxicity by activating BNIP3-dependent mitophagy through the JNK-ERK signaling pathway.
In summary, our findings demonstrated that pinocembrin can act as a potential therapeutic strategy for IH-induced neuroinflammation.
Obstructive sleep apnea (OSA) is a breathing disorder characterized by recurrent episodes of upper-airway collapse, resulting in intermittent hypoxia (IH) during sleep [1, 2]. IH has been shown to induce neuroinflammation and subsequent behavioral and neuropsychological deficits in the central nervous system (CNS) . A number of studies have demonstrated that IH triggers neuroinflammation through multiple signaling pathways, especially via oxidative stress, mitochondrial dysfunction, and an imbalance in pro- and anti-apoptotic gene cascades . However, the underlying mechanisms are complex and incompletely understood. Microglia are the resident macrophages in the CNS and are the principal sources of pro-inflammatory factors in CNS affected by OSA [4, 5]. In recent years, accumulating evidence has implicated activated microglial cells in both the development and maintenance of neuroinflammation in patients with OSA [6, 7]. Therefore, the inhibition of the abnormal activation of microglial and the protection of neurons from neuroinflammation are potential therapeutic strategies for OSA-related neurocognitive impairment.
Pinocembrin (5,7-dihydroxyflavone) is a natural flavonoid drug that can cross the blood-brain barrier, having antimicrobial, anti-inflammatory, antioxidant, and anticancer properties [8, 9]. Notably, several studies have shown that pinocembrin also has a neuroprotective effect, for which possible mechanisms may include reversed autophagic activity and inhibited cell apoptosis . These characteristics make pinocembrin an attractive molecule for the potential treatment of neuroinflammation in CNS diseases. Pinocembrin exerts its inhibitory effects against microglia activation by suppressing the phosphoinositide 3-kinase (PI3K)-Akt-nuclear factor (NF)-κB signaling pathway in lipopolysaccharide (LPS)-treated BV2 cells . Xi et al. also found that pinocembrin restricts M1 microglial polarization by inhibiting toll-like receptor 4 (TLR4), thus playing a protective role against intracranial hemorrhage (ICH) injury . Therefore, in the search to identify a neuroprotective agent that alleviates neuroinflammation, pinocembrin could provide unique functions in reducing reactive oxygen species (ROS) and modulating autophagy. However, the role of pinocembrin in the context of IH so far remains unclear.
Recent studies have shown that mitochondrial damage is involved in the activation of the nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome via mitochondrial ROS (mtROS) production . In our previous study, we highlighted the significant implications of NLRP3 in IH-induced mitochondrial damage . mtROS accumulation is also the major trigger of the NLRP3-mediated inflammatory response, which eventually promotes the maturation of pro-inflammatory cytokines such as interleukin (IL)-1β . Mitophagy, a type of selective autophagy, is traditionally recognized as a specific process that initiates the degradation of superfluous and damaged mitochondria to maintain mitochondrial homeostasis . However, if this procedure is not properly activated, superabundant inflammation induced by NLRP3 can be harmful to the host . In addition, the repressive autophagic activity during the activation of the NLRP3 inflammasome is attributed to compromised mitophagy .
BCL2-interacting protein 3 (BNIP3), primarily localized on the mitochondrium, is a potent and well-documented inducer of autophagy in many different cell types [1, 18, 19]. Through the Parkin-independent pathway of mitophagy, activated Bcl-2 and BNIP3 (or BNIP3-like, BNIP3/Nix) bind directly to LC3 to promote autophagic activity in a protective response against Bnip3 death signaling, mtROS overproduction, and NLRP3 inflammasome activation in CNS diseases [17, 20]. BNIP3-mediated mitophagy has been reported to protect against neuroinflammation . Additionally, Lei et al. showed that BNIP3-mediated mitophagy has beneficial effects on intracellular homeostasis and reduces microglial apoptosis in the tumor necrosis factor α (TNF-α)-treated BV2 cells . However, the association between the BNIP3-dependent mitophagy and the neuroprotective effect of pinocembrin is still unknown.
In this study, we demonstrate that pinocembrin improves behavior and cognitive deficits in IH mice via ameliorating microglia-induced neuroinflammation. Meanwhile, pinocembrin activates BNIP3-mediated mitophagy and inhibits NLRP3 inflammasome formation in hippocampal tissues in vivo. In the in vitro experiments, we show that pinocembrin prevents IH-elicited NLRP3 inflammasome activation in microglia, at least in part by enhancing mitophagy and attenuating mtROS production, which are mediated by the c-Jun N-terminal kinase (JNK)-extracellular regulated kinase (ERK)-BNIP3 signaling pathway. These data may provide a basis for using pinocembrin as a therapeutic intervention for OSA-associated neuroinflammation.
Methods and materials
Animals, cells, short hairpin RNA, antibodies, and reagents
The male C57BL/6J mice (6–7 weeks old, 20–22 g, n = 48) supplied by the Laboratory Animal Center at Fudan University (Shanghai, China) were raised in specific pathogen-free conditions. The murine microglial cell line BV-2 was obtained from the Chinese Academy of Medical Sciences (Beijing, China). We obtained pinocembrin (S3941) and 3-methyladenine (3-MA, S2767) from Selleck Chemicals (Houston, TX). Phosphatase inhibitor (P1045), SP600125 (S1876), and FR 108204 (SD5978) were obtained from Beyotime (Shanghai, China). We obtained ionized calcium-binding adaptor molecule 1 (Iba-1, ab65828), BNIP3 (ab10433), LC3 (ab51520), Beclin-1 (ab62557), NLRP3 (ab214185, ab4207 for immunofluorescence), Caspase-1 (ab1872), and Bax (ab32503) from Abcam; ATG7 (#8558), ATG5 (#12994), BNIP3/Nix (#12396), ASC (#67824), Caspase-3 (#9662), Bcl-2 (#3498), TOM20 (#42406, for western blot), and ubiquitin (#3933) from Cell Signal Technology (CST); TOM20 (AF1717, for immunofluorescence) from Beyotime; and Casase-1 p20 (sc-398715) from Santa Cruz Biotechnology. Fluorescence secondary antibodies were obtained from Jackson ImmunoResearch: goat anti-mouse IgG (Alexa Fluor® 555, 115-545-166), goat anti-rabbit IgG (Alexa Fluor® 488, 111-605-144), and donkey anti-goat IgG (Alexa Fluor® 555, 705-116-147). MitoSOX (M36008) was obtained from Thermo Fisher Scientific, and Cell Counting Kit-8 (CCK-8, CK04) was obtained from Solarbio® Life Science. Bnip3 small hairpin RNA (shRNA) plasmid was synthesized by GenePharma (Shanghai, China). The sequence of shRNA was as follows: 5′-GCCTCCGTCTCTATTTATAAT-3′.
Establishment of the IH animal model and drug treatment
A total of 48 mice were randomly divided into 4 groups of twelve: the normal air group (NA), the group treated with pinocembrin during 21 days of NA (NA + PIN), the 21-day IH group (IH), and the group treated with pinocembrin during 21 days of IH (IH + PIN). The mice from the PIN group were injected with 40 mg/kg pinocembrin every 2 days at 8:00 AM from day 1 to day 21 during the experiment (dissolved in PBS containing 5% povidone; i.p.). The mice from the NA and IH groups were injected with the vehicle (PBS containing 5% povidone; i.p.). The dosing, treatment regimens, and delivery route were based on previous work . Mice were maintained in 4 specially designed chambers (28.5 × 30.0 × 51.5 cm) under standard conditions (23–25 °C, 50–60% humidity, 12-h light/dark cycle) with regular chow and water. The animals were acclimatized for 1 week followed with 21-day IH or NA treatment. IH was administered for 8 h/day, from 8:00 AM to 4:00 PM (when these animals typically sleep), with the oxygen level oscillating between 21 and 5% with a period of 60 s. The oxygen concentration was automatically measured using an oxygen analyzer (Corporation, Shanghai, China) and was changed by a computerized system controlling gas outlets of oxygen and nitrogen, as previously described . Behavioral testing occurred during the final 5 days in IH or NA treatment during the dark phase and continued after the cessation of treatment (Fig. 1a). All the experimental protocols were approved by the Fudan University institutional animal care and use committee in accordance with the Helsinki Declaration of 1975.
Morris water maze
The Morris water maze (MWM) was used to assess spatial reference learning and memory of mice as previously described . The MWM consisted of a 1-m diameter circular pool, 0.6 m in height, filled to a level of 35 cm with water maintained at a temperature of 24 ± 2 °C. One hundred fifty milliliters of nontoxic white tempera paint was added to make pool water opaque. An escape platform was located in one of the quadrants of the pool and positioned 1 cm below the water surface. Mice were placed in other three different quadrants in turn and then the time taken (escape latency) for the mouse to find the escape platform was recorded. The mice were trained in 5 consecutive days, 3 trials per day with a 3-min inter-trial interval (ITI) for each mouse from 5:00 to 10:00 PM. After being placed into the pool, each mouse was allowed a maximum of 90 s to climb on the platform and then guided to the platform if they failed to find it. The position of the platform kept constant during the trials. Mice acquired spatial memory about the location of the escaped platform through these training sessions. The spatial memory of mice was tested 24 h later after the last training with the platform removed. To access the performance of mice in MWM, the percentage of time traveled in the target quadrant, platform-crossing times, and the average swimming speed on the sixth day were also recorded and analyzed.
Establishment of the IH microglial cell model and drug treatment
BV2 were cultured in DMEM medium (Hyclone), containing 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin in a 37 °C incubator with 5% CO2 until 50–60% confluent. The method of IH-treated BV2 cells was completed as previously . Briefly, cells were maintained in a 37 °C custom-made chamber with 5% CO2, in which O2 concentration was alternated between 0 and 22% every 30 min via injecting nitrogen or oxygen. The dissolved O2 was monitored by a laser O2 probe (Biospherix). The IH reached to 21% O2 and 5% O2 as normoxic and hypoxic values sensed by the cells. Transient transfections of BV2 cells with shRNA were performed by Lipofectamine™ 2000 (Invitrogen) according to the manufacturer’s instructions. Cells were cultured in 10% FBS DMEM medium for 48 h following 6-h transfection. Cells were pretreated with SP600125 or FR 108204 for 30 min before the administration of pinocembrin. 3-Methyladenine (3MA, 5 mM) was added to the culture medium for 6 h before exposing to IH.
Pinocembrin (purity > 99%) was dissolved in dimethylsulfoxide (DMSO) to make a 50-mM stock solution. We found that pinocembrin at doses of 20 μM could reduce cell viability (Fig. 4a). Therefore, we pretreated microglia with 1, 3, or 10 μM pinocembrin for 1 h before exposing them with IH. After exposurement, the cells were collected for flow cytometry analysis, immunofluorescent staining, qRT-PCR, or western blotting analysis. All experiments were performed in triplicate.
Histopathology and immunohistochemistry
After the behavior test, mice (5/group) were anesthetized with isoflurane. Half of the hemispheres (right) were removed and post-fixed in 4% paraformaldehyde (PFA) for 24 h at 4 °C. After dehydration, brain hemispheres were embedded in paraffin and then cut into 4-μm-thick sections. To assess pathological analysis, hematoxylin and eosin (H&E) staining was performed. For immunohistochemistry, slices from hippocampi were used for staining with anti-NLRP3 (1:500) overnight at 4 °C. The next day, the brain slices were incubated with specific IHC detection reagent for 2 h at 37 °C. Images were obtained with a light microscope (Olympus/DP70, Tokyo, Japan).
Mice (5/group) were anesthetized with isoflurane and sacrificed following behavior test. The whole brain tissues were extracted immediately and cut sagittally into hemispheres. Left hemispheres were fixed in ice-cold 4% PFA overnight at 4 °C and were then equilibrated in 30% sucrose. Next, 25-μm sagittal slices in the hippocampi were obtained with a freezing microtome. Sections were washed in cold PBS three times, blocked with 5% goat serum for 1 h, and incubated with Iba-1 antibody (1:500) and BNIP3 antibody (1:200) overnight at 4 °C.
BV2 microglial cells were cultivated on cell slides for staining. Cells were fixed by 4% paraformaldehyde for 30 min at 37 °C and then permeated cell membrane using 0.1% Triton X-100 for 5 min at room temperature. Subsequently, the cell slides were incubated with LC3 (1:500), BNIP3 (1:200), TOM20 (1:200), NLRP3 (1:500), or ASC (1:500) antibodies at 4 °C overnight. After incubating with secondary antibody for 1 h at room temperature, all the slices were counterstained with DAPI (Vector Laboratories, CA, USA), and photomicrographs were captured using an Olympus DP70 digital camera and software (Olympus, Japan) or a confocal microscope (Nikon, Japan). Samples were analyzed in a blinded manner using 3–5 fields randomly selected from each group. The co-localization analysis was performed by the ImageJ software.
RNA isolation and quantitative reverse transcriptase-PCR (qRT-PCR)
Total RNA was extracted from hippocampal lysates of mice (3/group) and BV2 cells using TRIzol reagent (Invitrogen, Carlsbad, CA). Relative mRNA levels were quantified by SYBR-Green Master Mix Plus (Toyobo, Osaka, Japan) according to the manufacturer’s protocol using a real-time PCR system (Applied Biosystems 7500HT; Applied Biosystems, Foster City, CA). The expressions of mRNA for TNF-α, iNOS, COX-2, IL-6, and IL-1β were performed in triplicate, and the samples were normalized by evaluating the GAPDH mRNA level. The primers specific to each mRNA used for the amplification were purchased from Sangon Biotech (Shanghai, China) and are listed in the supplementary material, Table S1.
For western blot analysis, the proteins from hippocampal tissues (4/group), BV2 cells, and mitochondrial fraction were separated in 10% or 12.5% SDS-polyacrylamide gel, and polyvinylidene difluoride (PVDF) membranes were incubated with specific primary antibodies at 4 °C overnight. Bands were detected by ECL (Amersham Pharmacia Biotech, Piscataway, NJ) following 1-h incubation with HRP-conjugated secondary antibody (1:5000) at room temperature. ImageJ software (NIH, Bethesda, MD) was used for densitometry analysis, and the relative protein expressions were normalized against GAPDH or TOM20 (mitochondrial fraction, mito.). All experiments were performed in triplicate.
Analysis of apoptosis
Apoptotic neuron was detected using terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining according to the manufacturer’s protocol (in situ cell death detection kit; Roche, Netley, NJ). The number of TUNEL-positive cells was counted in a blinded manner using 5 individual images.
BV2 cells were collected and washed with PBS twice, and then cell apoptosis was assessed by flow cytometry and immunoblot analysis of caspase-3, Bcl-2, and Bax. Flow cytometry was performed by labeling annexin V-fluorescein isothiocyanate (FITC) and propidine iodide (PI) according to the manufacturer’s instructions (BD Biosciences, 556547). Cell mortality was analyzed by BD LSR Fortessa, and quantification analysis was conducted by FlowJo software (Tree Star, San Carlos, CA). The upper and lower right quadrants show the proportions of the late (Annexin V+/PI+) and the early (Annexin V+/PI−) apoptotic cells, respectively.
Isolation of mitochondria
Microglial mitochondria were isolated and purified using the Cell Mitochondria Isolation Kit (Beyotime Biotech, C3601) as per the manufacturer’s protocol. Cell pellets (5 × 106) were resuspended in 200 μl of Mitochondria Isolate Reagent after washing twice with cold PBS, incubated on ice, and then homogenized with a glass homogenizer. The homogenate was centrifuged at 600g for 10 min. The supernatant was transferred to a new tube and spun at 11,000g for 10 min at 4 °C to pellet mitochondria. The mitochondrial pellet was washed with cold PBS and stored at 4 °C until further processing.
Cell viability assay
Cell viability was measured using the CCK-8 assay (Dojindo, Kyushu Island, Japan). At brief, BV2 microglial cells were seeded in 96-well plates, transient transfected with shRNA or pretreated with inhibitors, and then treated with various concentrations of pinocembrin under IH condition for 3, 6, 12, or 24 h. The cells were then treated with 10 μL/100 μL medium CCK-8 assay reagent and incubated for 2 h at 37 °C in a 5% CO2 incubator. Optical density (OD) was measured at 450 nm under a microplate spectrophotometer (Thermo Fisher Scientific, Camarillo, CA, USA).
Analysis of mitochondrial ROS (mtROS)
Mitochondrial ROS (mtROS) level in living BV2 cells was detected by Mito SOX Red (Invitrogen) assay according to the manufacturer’s instructions. Briefly, the cells were seeded in 6-well plates with a density of 5 × 105/ml with 3 parallel wells in each group. After various treatments, cells were stained with MitoSOX Red probe at a final concentration of 5 μM at 37 °C in the dark for 10 min. Then, cells were washed thoroughly with PBS, and the activity of mtROS was analyzed using FACSCalibur (BD Biosciences). Quantification was conducted by FlowJo software (Tree Star, San Carlos, CA).
Mitochondrial membrane potential (MMP)
Changes in MMP were determined using a JC-1 mitochondrial membrane potential assay kit (Beyotime, China) according to the manufacturer’s instructions. All samples were observed under an inverted microscope (Olympus IX73, Japan) or estimated quantitation of fluorescence intensity using FACSCalibur (BD Biosciences). The loss of MMP was reflected by the ratio of aggregates (red fluorescence) to monomer (green fluorescence).
Transmission electron microscopy (TEM)
BV2 cells were harvested in 1 mm3 and fixed in ice-cold 2.5% glutaraldehyde. Next, samples were dehydrated in ethanol (with 3% uranyl acetate), embedded in a mixture of epoxy resin and propylene oxide for 24 h. After a 70-nm-thick sample section staining with lead citrate, the mitochondrial morphology and mitophagosomes were detected under a transmission electron microscope (JEM 1011, Japan) by two blinded pathologists.
Total protein lysate from BV-2 cells was immunoprecipitated with 1 μg of anti-LC3 antibody overnight at 4 °C. Protein A agarose beads (30 μl, Cell Signaling Technology) was added to the mixture and incubated at 4 °C for 4 h. The beads were collected by centrifugation at 12,000×g for 60 s at 4 °C and then washed 3 times by immunoprecipitation buffer. Protein complexes were resuspended in 5× loading buffer and boiled for 10 min. Then, the collected supernatant was used in western blotting.
All statistical analyses were conducted using SPSS 25.0 software and Prism 7.0 (GraphPad). Differences between two groups were analyzed by two-tailed unpaired Student’s t test. One-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was used for multiple comparisons. In addition, escape latencies during the training of WMW were analyzed by two-way repeated measures ANOVA, while platform-crossing times were analyzed by ANOVA on ranks. Qualitative data were expressed as means ± standard error of the mean (SEM). Significance was considered when p < 0.05.
Pinocembrin improves behavior and cognitive deficits in IH mice
To determine the effects of pinocembrin on spatial learning and memory of the IH mice, the MWM test was performed. The mice were trained to remember the location of the escape platform for 5 consecutive days, and the data showed that the latency was significantly increased for IH-treated mice as compared to the NA group (p < 0.05). The results also revealed the preservation of learning ability in mice treated with pinocembrin relative to the mice after exposures with IH (p < 0.05, Fig. 1b). Meanwhile, the memory activities were then tested after the platform had been removed. During the probe trail, the mice from the IH group spent less time in the target quadrant than those from the NA group (p < 0.01). Pinocembrin treatment obviously rescued the cognitive decline induced by IH (p < 0.05; Fig. 1c). Moreover, compared to the NA group, the frequency to cross the platform was decreased in the IH group. This decrease was reversed by pinocembrin treatment (p < 0.05; Fig. 1d). In addition, swim speed of the IH and pinocembrin treatment groups did not significantly change compared to the NA group, thereby suggesting no differences between the groups in terms of locomotor ability or coordination (Fig. 1e). Taken together, these results suggest that pinocembrin treatment can alleviate the cognitive decline induced by IH in mice.
Pinocembrin ameliorates microglia-mediated neuroinflammation in IH mice
To determine whether pinocembrin protects the neurons from IH-induced damage, the histological photographs for the examination of neuronal apoptosis from the different groups are shown in Fig. 2a. The neurons in CA1 regions of the hippocampus were arranged in order in the NA and PIN groups. IH treatment significantly reduced the number of neurons and resulted in a severe neuronal degeneration at the hippocampus, with nucleolus disappears and triangulated neuronal body (black arrow), while in the pinocembrin (40 mg/kg) group, neurons had enlarged soma and normal morphology compared with the IH group. We then used the TUNEL assay to assess cell apoptosis in experimental models of sleep apnea. TUNEL staining showed that few apoptotic neurons were detected in the hippocampus of mice in the NA and PIN groups and that higher numbers of TUNEL-positive neurons were found in the IH group (p < 0.01 vs. NA group). Administration of pinocembrin (40 mg/kg) significantly decreased the proportion of TUNEL-positive neurons in the hippocampus in IH-treated mice (p < 0.05; Fig. 2b, c).
Abnormally activated microglia are reported to be the main cells mediating neuroinflammation . At the completion of 21-day IH treatment, the expression of Iba-1 was assessed in hippocampus tissues via immunofluorescent staining. Hippocampal tissue from IH group mice showed a great deal of Iba-1-positive cells relative to the NA group (p < 0.01). Compared with the IH group, treatment with 40 mg/kg pinocembrin significantly reduced the number of Iba-1-positive cells in the hippocampal tissue (p < 0.05; Fig. 2b, c), demonstrating that pinocembrin administration inhibited the infiltration and activation of microglia in the hippocampus after IH exposure. We then tested the effects of pinocembrin on the production of inflammatory mediators in hippocampi with qRT-PCR. The results showed that pinocembrin treatment visibly suppressed the production of IH-induced inflammatory cytokine (Fig. 2d). Taken together, these data reveal that pinocembrin treatment can ameliorate microglia-mediated neuroinflammation in IH mice.
Pinocembrin inhibits NLRP3 inflammasome activation and enhances BNIP3-mediated mitophagy in hippocampi of IH mice
We determined the effects of pinocembrin on the expression of NLRP3, ASC, and cleaved caspase-1 in the hippocampus of the mice after exposure with IH by immunohistochemistry and western blotting, respectively. Compared with the NA group, IH exposure led a marked increase in the expression of NLRP3 in the hippocampus. Pinocembrin treatment can observably reverse these changes (Fig. 3a). Similar results were obtained from western blot analysis. As shown in Fig. 3b, IH mice had increased protein levels of NLRP3, cleaved caspase-1, and ASC in the hippocampus compared to the NA group. The levels of those proteins were markedly reduced by pinocembrin treatment after exposing to IH. These results indicate that the NLRP3 inflammasome activation may contribute to IH-induced hippocampal inflammation, which could inhibit pinocembrin.
Next, to detect the BNIP3-related mitophagic activity in the hippocampus of mice, immunofluorescence stain and western blotting were performed. As illustrated in Fig. 3c, typical immunofluorescence images of doubling staining using BNIP3/IBA-1 revealed that administration of 40 mg/kg pinocembrin can further increase BNIP3 protein expression after IH exposure. Furthermore, western blot analysis of proteins from the hippocampus of mice showed that the expressions of BNIP3/NIX, BNIP3, and LC3 were low in the NA group. In comparison, the expressions of BNIP3/NIX, BNIP3, and LC3 were significantly higher in the IH and PIN groups. The levels of TOM20 protein was in a reverse tendency, demonstrating the activation of BNIP3-mediated mitochondrial autophagy. Additionally, administration of 40 mg/kg pinocembrin companied with IH exposure further activated BNIP3-relative mitophagy (Fig. 3d). Therefore, these findings demonstrate that pinocembrin can further activate BNIP3-mediated mitophagy in the hippocampus of IH mice.
Pinocembrin exerts positive effects on IH-treated microglia in vitro
To establish an in vitro IH-activated microglial model, we incubated BV2 cells in an IH environment, as previously described . Cell viability was significantly lower in the IH-treated BV2 cells than in the NA cells at 24 h. Therefore, long-term IH exposure can be detrimental to these cells. We investigated the therapeutic and cytotoxic effects of pinocembrin on IH-treated BV2 cells. The cells were pretreated with pinocembrin at a concentration of 1, 3, 10, or 20 μM for 1 h before exposure with IH for 24 h, and then their viability was evaluated with a CCK-8 assay. As shown in Fig. 4a, there was a significant increase in the cell survival rate in the IH + 10 μM group compared with that in the IH group. We also found that 20 μM pinocembrin elicited a robust inhibitory effect on cell viability, indicating that 10 μM is the optimum concentration of pinocembrin for BV2 cells. Immunoblotting analysis of whole-cell lysates showed that the expression of cleaved caspase-3 and Bax was significantly elevated and the Bcl-2 protein level was reduced (Fig. 4b). It is generally believed that inflammatory responses are implicated in cellular oxidative stress and the activation of the NLRP3 inflammasome, which are vital for the fates of cells [16, 25]. Immunoblotting analysis showed that pinocembrin exerted a dose-dependent inhibitory effect on the activation of NLRP3 inflammation (1, 3, or 10 μM), evident as reduced levels of NLRP3, cleaved caspase-1, and ASC (an apoptosis-associated speck-like protein containing a caspase-recruitment domain) proteins (Fig. 4c, d). These data indicate that pinocembrin alleviates IH-induced cytotoxicity by preventing the accumulation of NLRP3 inflammasomes and by decreasing cell apoptosis.
We then assessed autophagy and mitophagy in the microglia, two of the major mechanisms in the CNS that keep inflammation in check . To examine the relationship between the pinocembrin-mediated neuroprotective effect and mitophagy, we examined the activities of autophagy and mitophagy with an immunoblotting analysis. An immunoblotting analysis of ATG7, P62, Beclin-1, ATG5, BNIP3/Nix, BNIP3, and LC3-II revealed the dose-dependent activation of autophagy and mitophagy by treating with pinocembrin (Fig. 4e, f). Further examination by using TEM confirmed mitochondrial damages and mitophagosome formation (red arrow) in BV2 cells, which were rarely observed in microglial cells from the NA group. IH exposure exhibited profound effects on mitochondrial structure, including the increase in vacuoles in the mitochondrial matrix, mitochondrial fragmentation and swelling, and loss of cristae. In addition, compared with the IH group, there were plenty of autophagosome and mitophagosome formations (red arrow) observed in the cytoplasm of the microglia in the IH + PIN group (Fig. 4g). Taken together, these results demonstrate that Bnip3-related mitophagy is involved in the protective effect of pinocembrin.
Pinocembrin suppresses IH-induced microglial cell damage via BNIP3-dependent mitophagy
To further investigate the role of BNIP3 in the neuroprotective action of pinocembrin, we transfected cells with shRNA or incubated with 3-MA (an inhibitor of autophagy, 5 mM) before pinocembrin treatment (10 μM). We first used western blotting to evaluate the changes in autophagic and mitophagic activities. Our results indicated that silencing BNIP3 or pretreatment with 3MA neutralized the effect of pinocembrin and reduced the levels of both autophagy and mitophagy in IH-treated microglial cells (Fig. 5a, b). We then used double immunofluorescent staining for the autophagic markers LC3 (green) and BNIP3 (red) in microglial cells to clarify the changes in BNIP3-mediated mitophagy. The stain intensity of LC3 staining and the numbers of cells expressing BNIP3 were clearly increased in the IH microglia treated with pinocembrin. However, after transfection with shBNIP3 or pretreatment with 3MA, pinocembrin no longer enhanced mitophagy after IH exposure. As shown in Fig. 5c and d, a number of puncta (yellow) showed faint immunofluorescence in the shBNIP3 and 3MA groups. Moreover, the co-localization of LC3 and BNIP3 demonstrated the declined mitophagosome formation after BNIP3 inhibition.
To examine the changes in mitochondrial function more closely, the levels of MMP and mtROS production were also assessed. According to our in vitro data, pinocembrin treatment markedly restored the disrupted MMP (red to green ratio, p < 0.05, 2.80 ± 0.89% vs. 3.84 ± 1.11%) and attenuated the release of mtROS (p < 0.05, 44.2 ± 1.88% vs. 31.30 ± 2.25%). After transfection with shRNA or stimulation with 3MA, the positive effects of pinocembrin on IH microglia were absolutely abrogated. The loss of MMP was dramatically enhanced by BNIP3 deletion or 3MA treatment (2.45 ± 1.34%; 2.27 ± 2.88%), and mtROS were greatly upregulated (49.30 ± 1.79%; 52.03 ± 3.16%), as shown in Fig. 6a–c. The inhibition of BNIP3-dependent mitophagy also increased the proportion of apoptotic cells, despite pinocembrin treatment (12.03 ± 3.01%), as shown in Fig. 6d. In summary, these results show that pinocembrin maintains mitochondrial homeostasis and neutralizes excessive oxidative stress via Bnip3-dependent mitophagy. We then investigated whether BNIP3-dependent mitophagy is implicated in the inhibitory effect of pinocembrin on the NLRP3-mediated inflammatory response. As shown in Fig. 6e, the relative expression of mRNAs for TNF-α, iNOS, COX-2, IL-6, and IL-1β increased distinctly in the shBNIP3- or 3MA-treated BV2 cells, despite treatment with pinocembrin. Furthermore, immunoblotting analysis confirmed the inhibition of BNIP3-dependent mitophagy increased NLRP3 inflammasome activation, which abolished the therapeutic effect of pinocembrin on IH microglia (Fig. 6f, g). Taken together, these results indicate that pinocembrin exerts a protective effect in the context of IH by decreasing mtROS production and NLRP3 inflammasome formation, which relied on the activation of BNIP3-dependent mitophagy.
Pinocembrin activates Bnip3-dependent mitophagy via the JNK-ERK signaling pathway
It has been reported that BNIP3-induced mitophagy occurs via JNK and ERK MAPK activation [7, 19]. To further investigate the underlying molecular mechanisms of pinocembrin-mediated neuroprotection, the effects of pinocembrin on IH-elicited JNK and ERK phosphorylation were tested. The phosphorylation of JNK and ERK was significantly increased in the IH + pinocembrin group, and in particular, the level of p-ERK was approximately 1.5-fold higher than that in the IH group (Fig. 7a, b). We then added SP600125 (JNK inhibitor, 10 μM) or FR 108204 (ERK inhibitor, 10 μM) to detect the changes in cell viability, cell apoptosis, and mtROS-NLRP3 signaling pathway when the activity of JNK or ERK was inhibited, respectively. As shown in Fig. 7c, pinocembrin alone promoted the viabilities of IH microglia as compared to the IH group. The cell viabilities determined by CCK-8 assay of the inhibitor groups were obviously lower than those of pinocembrin-treated cells without SP600125 or FR 108204. After incubation with MitoSOX Red probe, the activity of mtROS in microglia was detected with flow cytometry. The levels of mtROS decreased greatly in cells treated with pinocembrin (24.23 ± 2.01%), whereas nearly 2-fold the increased level of oxidative stress was detected when the pinocembrin group was pretreated with inhibitor (SP600125, 60.17 ± 2.01%; FR 108204, 58.67 ± 1.77%; Fig. 7d). The rate of cell apoptosis was determined with immunoblotting. As shown in Fig. 7e, the dephosphorylation of p-JNK or p-ERK significantly inhibited the expression of Bcl-2 (an anti-apoptotic protein), suggesting that the inhibition of JNK and ERK activity exacerbates the detrimental actions of IH. Further double staining of NLRP3 (red) and ASC (green) revealed a marked increase in inflammasome formation in IH microglia treated with both inhibitors (Fig. 7f).
We then explored whether the phosphorylation of JNK or ERK was the upstream of BNIP3-dependent mitophagy in the pinocembrin-treated microglia. As shown in Fig. 8a, levels of BNIP3 and the LC3 complex increased upon pinocembrin pretreatment in BV2 cells. However, the interaction between BNIP3 and LC3 was decreased dramatically when microglia were co-incubated with inhibitors, indicating the inhibition of BNIP3-dependent mitophagy. To further confirm the role of p-JNK and p-ERK in pinocembrin-induced mitophagy, we performed western blotting using the lysates from mitochondrial fraction of BV2 cells. In contrast to the IH + pinocembrin group, inhibitors significantly abolished mitochondrial co-localization with P62 and mitochondrial ubiquitination in pinocembrin-treated microglial cells (Fig. 8b). Moreover, as shown in Fig. 8c, the BV2 cells showed further increases in BNIP3 (red) and TOM20 (mitochondrial-related protein, green) protein expression and their co-localization in response to pinocembrin exposure. Pretreatment with inhibitors prominently reversed these responses in pinocembrin-treated BV2 cells. Further immunofluorescent staining of LC3 (green) and BNIP3 (red) also showed that both SP600125 and FR 108204 suppressed the activation of BNIP3-dependent mitophagy, indicating that the level of BNIP3-dependent mitophagy was regulated by the activation of JNK and ERK (Fig. 8d). Taken together, these data demonstrate that the JNK-ERK signaling pathway is involved in the function of pinocembrin in maintaining mitochondrial homeostasis, inhibiting inflammation, and protecting microglial cell apoptosis during IH exposure via BNIP3-dependent mitophagy (Figure S1).
The present study demonstrated that the administration of pinocembrin can efficiently improve cognitive deficits and ameliorate brain injury in IH mice, evidenced by restoring microglial mitophagy and reducing neuronal apoptosis and hippocampal inflammation. This study also highlights a new signaling mechanism by which pinocembrin exerts its neuroprotective effects during IH via enhancing BNIP3-dependent mitophagy. Although several previous studies have proven the therapeutic action of pinocembrin during ICH [10, 12], few studies have focused on its neuroprotective effects during IH caused by OSA. To our knowledge, our data show for the first time that the pharmacological mechanism of pinocembrin involves the regulation of mitophagy and subsequently the inhibition of cell apoptosis and NLRP3-mediated inflammation during IH both in vivo and in vitro. Additionally, we suggest that BNIP3 is a potential target for the control of excessive mtROS production or NLRP3 inflammasome accumulation in brain injury and that pinocembrin has therapeutic potential for OSA-associated neuroinflammation.
One of the pathophysiological hallmarks of OSA is the presence of neuroinflammation, which is closely associated with the microglia . It has also been known that oxidative stress and inflammation have negative mechanistic effects on the microglia, leading to their apoptosis. Damaged microglia release a large amount of pro-inflammatory cytokines, which further promote the cascade reactions of inflammation . A previous study showed that the suppression of cell apoptosis can alleviate microglia-mediated inflammation . Generally, the moderate activation of inflammation favors neural protection, but can lead to neurotoxicity when excessive . Moreover, increasing evidence indicates that the NLRP3-associated inflammatory response plays an important role in the development of neuroinflammation . Therefore, protecting microglia against inflammation-induced apoptosis is a strategy for alleviating neuroinflammation. In the last few years, increasing studies have shown that mitophagy, a mitochondrium-specific process of “self-digestion,” is an intrinsic anti-inflammatory mechanism, which initiates the clearance of dysfunctional mitochondria and restricts excessive inflammatory cytokine production, ultimately inhibiting nerve inflammation . Therefore, our observations in the present study show that a potential mitophagy agonist (pinocembrin), which attenuates IH-induced mtROS production and the NLRP3-related inflammatory response by upregulating of BNIP3 expression, may offer a novel therapeutic strategy for neuroinflammation-related diseases.
Previous studies have demonstrated that pinocembrin has anti-inflammatory properties, which are absorbed and metabolized well after its oral administration . In vitro experiments have also shown that pinocembrin inhibits LPS-induced inflammatory cytokine secretion in RAW264.7 cells . Zhao et al. suggested that pinocembrin mitigates cell death by increasing autophagic activity, thus protecting the brain from ischemia/reperfusion injury . In the present study, we examined the positive role of pinocembrin in IH-mediated brain tissue impairment to determine the ameliorative potential of pinocembrin in this context. Our findings indicate that the exposure of microglial cells to IH markedly reduced MMP and increased NLRP3-related inflammation, which were accompanied by the low-level upregulation of the mitophagy markers, BNIP3 and BNIP3/Nix. However, by using the pinocembrin, both autophagy and BNIP3-dependent mitophagy increased dramatically, inhibiting the mtROS-NLRP3 axis and inflammatory cytokine production. Therefore, our data show that pinocembrin inhibits mitochondrial damage and cell apoptosis by functionally activating BNIP3. Although pinocembrin provides a therapeutic advantage in neuroinflammatory states by upregulating BNIP3-dependent mitophagy in microglia, the exact role of autophagy in this process remains an enigma. In contrast, some investigators have reported that pinocembrin suppresses cell apoptosis by inhibiting autophagy [28, 29], which may be attributable to differences in the cell types examined.
Previous studies indicated that BNIP3 induces autophagy, accompanied by the loss of MMP and cell death [18, 30, 31]. Nevertheless, our results show that BNIP3 acts as a protective regulator during IH exposure, inducing mitophagosome formation and removing unhealthy mitochondria from microglial cells. Besides, BNIP3 deficiency results in impaired mitophagy which further accelerates cleaved caspase-1 release via NLRP3 inflammasome activation, indicating that BNIP3-dependent mitophagy acts as a pivotal brake to restrain mtROS-activated inflammatory cytokine secretion. We also demonstrate that BNIP3 controls the quality of the mitochondria by regulating MMP and mtROS production during IH . Consistent with our data, Dhingra and his colleagues indicated that the BNIP3-mediated mitophagic pathway opposes the cell apoptotic pathway (involving caspase-3) because the autophagy of damaged mitochondria counteracts cell death signaling . Moriyama et al.  showed that BNIP3-induced autophagy, triggered by the activation of JNK and ERK MAPK, played a crucial role in protecting mitochondrial homeostasis against irradiation-induced cell death. Recently, accumulating evidence has shown the protective effects of BNIP3 induction under hypoxic conditions, which is attributed to the upregulation of hypoxia-inducible factor 1 (HIF-1) . However, the role of BNIP3 in hypoxia-induced cell death is controversial. Rikka et al. proved that BNIP3 contributes to the impairment of the mitochondrial respiratory chain, whereas autophagy is induced in response to Bnip3 and BNIP3L, whether or not the intrinsic (mitochondrial) cell death pathway is activated [31, 33]. As a consequence, whether BNIP3 activates mitophagy and then participates in the alleviation of cell death requires clarification. Interestingly, it has been documented that hypoxia-induced mitophagy is mediated by various factors in different cell types . Although we have found that BNIP3-dependent mitophagy is associated with the neuroprotective effects of pinocembrin, it is still vague whether it plays a dominant role in the inhibition of IH-induced neuroinflammation. The relationships between pinocembrin and various mitophagy receptors have not been described in this study and warrant further research.
In conclusion, pinocembrin significantly reverses the IH-induced cognitive decline and neuroinflammation in IH mice. In particular, our observations show that pinocembrin protects microglial cells against IH-induced cytotoxicity by activating BNIP3-dependent mitophagy through the JNK-ERK signaling pathway. Taken together, our preliminary experiments suggest that mtROS and NLRP3-mediated inflammation play key roles in the pathogenic processes driven by IH-induced microglia in OSA patients, which can be offset by pinocembrin-enhanced mitochondrial autophagy. Overall, these findings demonstrate that pinocembrin is a potential therapeutic agent for OSA-associated neuroinflammation.
Availability of data and materials
All data generated and/or analyzed during this study are included in this article.
BCL2-interacting protein 3
Central nervous system
Extracellular regulated kinase
Fetal bovine serum
Hematoxylin and eosin
c-Jun N-terminal kinase
Morris water maze
Nucleotide-binding domain-like receptor protein 3
Obstructive sleep apnea
Reactive oxygen species
Standard error of the mean
Terminal deoxynucleotidyl transferase dUTP nick-end labeling
Toll-like receptor 4
Transmission electron microscopy
Tumor necrosis factor-α
Zhang SXL, Wang Y, Gozal D. Pathological consequences of intermittent hypoxia in the central nervous system. Compr Physiol. 2012;2(3):1767.
Yang Q, Wang Y, Feng J, Cao J, Chen B. Intermittent hypoxia from obstructive sleep apnea may cause neuronal impairment and dysfunction in central nervous system: the potential roles played by microglia. Neuropsychiatr Dis Treat. 2013;9:1077–86.
Liu S, Wang Z, Xu B, Chen K, Ren L, Sun J. Intermittent hypoxia reduces microglia proliferation and induces DNA damage in vitro. Chest. 2016;149(4, Supplement):A577.
Wu H, Chen Q. Hypoxia activation of mitophagy and its role in disease pathogenesis. Antioxid Redox Signal. 2015;22(12):1032–46.
Liu S, Sun JY, Ren LP, Chen K, Xu B. Propofol attenuates intermittent hypoxia induced up-regulation of proinflammatory cytokines in microglia through inhibiting the activation of NF-Bkappa/p38 MAPK signalling. Folia Neuropathol. 2017;55(2):124–31.
Shi Y, Guo X, Zhang J, Zhou H, Sun B, Feng J. DNA binding protein HMGB1 secreted by activated microglia promotes the apoptosis of hippocampal neurons in diabetes complicated with OSA. Brain, Behavior, and Immunity. 2018;73:482–92.
Karunakaran I, Alam S, Jayagopi S, Frohberger SJ, Hansen JN, Kuehlwein J, Hölbling BV, Schumak B, Hübner MP, Gräler MH, Halle A, van Echten-Deckert G. Neural sphingosine 1-phosphate accumulation activates microglia and links impaired autophagy and inflammation. Glia. 2019;67(10):1859–72.
Lan X, Wang W, Li Q, Wang J. The natural flavonoid pinocembrin: molecular targets and potential therapeutic applications. Mol Neurobiol. 2016;53(3):1794–801.
Borriello M, Iannuzzi C, Sirangelo I. Pinocembrin protects from AGE-induced cytotoxicity and inhibits non-enzymatic glycation in human insulin. Cells-Basel. 2019;8(5):385.
Zhao G, Zhang W, Li L, Wu S, Du G. Pinocembrin protects the brain against ischemia-reperfusion injury and reverses the autophagy dysfunction in the penumbra area. Molecules. 2014;19(10):15786–98.
Zhou LT, Wang KJ, Li L, Li H, Geng M. Pinocembrin inhibits lipopolysaccharide-induced inflammatory mediators production in BV2 microglial cells through suppression of PI3K/Akt/NF-kappaB pathway. Eur J Pharmacol. 2015;761:211–6.
Lan X, Han X, Li Q, Li Q, Gao Y, Cheng T, Wan J, Zhu W, Wang J. Pinocembrin protects hemorrhagic brain primarily by inhibiting toll-like receptor 4 and reducing M1 phenotype microglia. Brain Behav Immunity. 2017;61:326–39.
Gurung P, Lukens JR, Kanneganti T. Mitochondria: diversity in the regulation of the NLRP3 inflammasome. Trends Mol Med. 2015;21(3):193–201.
Wu X, Chang SC, Jin J, Gu W, Li S. NLRP3 inflammasome mediates chronic intermittent hypoxia-induced renal injury implication of the microRNA-155/FOXO3a signaling pathway. J Cell Physiol. 2018;233(12):9404–15.
Frank M, Duvezin-Caubet S, Koob S, Occhipinti A, Jagasia R, Petcherski A, Ruonala MO, Priault M, Salin B, Reichert AS. Mitophagy is triggered by mild oxidative stress in a mitochondrial fission dependent manner. Biochim Biophys Acta. 2012;1823(12):2297–310.
Kim M, Yoon J, Ryu J. Mitophagy: a balance regulator of NLRP3 inflammasome activation. Bmb Rep. 2016;49(10):529–35.
Xu Y, Shen J, Ran Z. Emerging views of mitophagy in immunity and autoimmune diseases. Autophagy. 2020;16(1):3-17.
Wang Y, Liu N, Lu B. Mechanisms and roles of mitophagy in neurodegenerative diseases. Cns Neurosci Ther. 2019;25(7):859-75.
Moriyama M, Moriyama H, Uda J, Kubo H, Nakajima Y, Goto A, Morita T, Hayakawa T. BNIP3 upregulation via stimulation of ERK and JNK activity is required for the protection of keratinocytes from UVB-induced apoptosis. Cell Death Dis. 2017;8(2):e2576.
Hamacher-Brady A, Brady NR, Gottlieb RA, Gustafsson AB. Autophagy as a protective response to Bnip3-mediated apoptotic signaling in the heart. Autophagy. 2006;2(4):307–9.
Iyalomhe O, Swierczek S, Enwerem N, Chen Y, Adedeji MO, Allard J, Ntekim O, Johnson S, Hughes K, Kurian P, TO O. The role of hypoxia-inducible factor 1 in mild cognitive impairment. Cell Mol Neurobiol. 2017;37(6):969–77.
Lei Q, Tan J, Yi S, Wu N, Wang Y, Wu H. Mitochonic acid 5 activates the MAPK–ERK–yap signaling pathways to protect mouse microglial BV-2 cells against TNFα-induced apoptosis via increased Bnip3-related mitophagy. Cell Mol Biol Lett. 2018;23(1):14.
Soromou LW, Chu X, Jiang L, Wei M, Huo M, Chen N, Guan S, Yang X, Chen C, Feng H, Deng X. In vitro and in vivo protection provided by pinocembrin against lipopolysaccharide-induced inflammatory responses. Int Immunopharmacol. 2012;14(1):66–74.
Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Meth. 1984;11(1):47–60.
Li H, Miao W, Ma J, Xv Z, Bo H, Li J, Zhang Y, Ji LL. Acute exercise-induced mitochondrial stress triggers an inflammatory response in the myocardium via NLRP3 inflammasome activation with mitophagy. Oxid Med Cell Longev. 2016;2016:1–11.
Jin X, Liu MY, Zhang DF, Zhong X, Du K, Qian P, Yao WF, Gao H, Wei MJ. Baicalin mitigates cognitive impairment and protects neurons from microglia-mediated neuroinflammation via suppressing NLRP3 inflammasomes and TLR4/NF-κB signaling pathway. Cns Neurosci Ther. 2019;25(5):575–90.
Thangaraj A, Periyasamy P, Guo M, Chivero ET, Callen S, Buch S. Mitigation of cocaine-mediated mitochondrial damage, defective mitophagy and microglial activation by superoxide dismutase mimetics. Autophagy. 2019:1–24.
Zheng Y, Wang K, Wu Y, Chen Y, Chen X, Hu CW, Hu F. Pinocembrin induces ER stress mediated apoptosis and suppresses autophagy in melanoma cells. Cancer Lett. 2018;431:31–42.
Tao J, Shen C, Sun Y, Chen W, Yan G. Neuroprotective effects of pinocembrin on ischemia/reperfusion-induced brain injury by inhibiting autophagy. Biomed Pharmacother. 2018;106:1003–10.
Qi Y, Tian X, Liu J, Han Y, Graham AM, Simon MC, Penninger JM, Carmeliet P, Li S. Bnip3 and AIF cooperate to induce apoptosis and cavitation during epithelial morphogenesis. J Cell Biol. 2012;198(1):103–14.
Rikka S, Quinsay MN, Thomas RL, Kubli DA, Zhang X, Murphy AN, Gustafsson ÅB. Bnip3 impairs mitochondrial bioenergetics and stimulates mitochondrial turnover. Cell Death Differ. 2011;18(4):721–31.
Lee HJ, Jung YH, Choi GE, Ko SH, Lee S, Lee SH, Han HJ. BNIP3 induction by hypoxia stimulates FASN-dependent free fatty acid production enhancing therapeutic potential of umbilical cord blood-derived human mesenchymal stem cells. Redox Biol. 2017;13:426–43.
Dhingra A, Jayas R, Afshar P, Guberman M, Maddaford G, Gerstein J, Lieberman B, Nepon H, Margulets V, Dhingra R, Kirshenbaum LA. Ellagic acid antagonizes Bnip3-mediated mitochondrial injury and necrotic cell death of cardiac myocytes. Free Radic Bio Med. 2017;112:411–22.
The study was financially supported by the National Natural Science Foundation of China (grant nos. 82000095 & 81800089), the fund for Fundamental Research Funds for the Central Universities (22120180576), and the clinical research fund of Zhongshan Hospital to Xu Wu (2020ZSQN083).
Ethics approval and consent to participate
All animal experimental protocols were approved by the Fudan University institutional animal care and use committee in accordance with the Helsinki Declaration of 1975.
Consent for publication
The authors declare no conflict of interest. All the authors listed have approved the manuscript.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Gong, LJ., Wang, XY., Gu, WY. et al. Pinocembrin ameliorates intermittent hypoxia-induced neuroinflammation through BNIP3-dependent mitophagy in a murine model of sleep apnea. J Neuroinflammation 17, 337 (2020). https://doi.org/10.1186/s12974-020-02014-w
- Obstructive sleep apnea (OSA)